Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2014

Open Access 01-12-2014 | Letter to the Editor

Antibodies reacting with Simian Virus 40 capsid protein mimotopes in serum samples from patients affected by uveal melanoma

Authors: Ilaria Bononi, Paolo Perri, Alice Begnardi, Alessandra Martini, Elisa Mazzoni, Silvia Bosi, Silvia Pietrobon, Adolfo Sebastiani, Mauro Tognon, Fernanda Martini

Published in: Journal of Hematology & Oncology | Issue 1/2014

Login to get access

Abstract

The uveal melanoma (UM) is the most common human intraocular tumour. Simian Virus 40 (SV-40) is a small DNA tumor virus detected in some malignancies, including the cutaneous melanoma. In this study an indirect ELISA using synthetic peptides that mimic SV-40 antigens, was employed to detect antibodies against SV-40 in serum samples from UM patients. Our report indicates a significant higher prevalence of antibodies against SV-40 capsid protein antigens in serum samples from UM patients compared to controls. Our data suggest an association between UM and SV-40, indicating that patients affected by uveal melanoma tested SV-40-positive could be treated by innovative therapies.
Appendix
Available only for authorised users
Literature
1.
Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM, Harbour JW: Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci. 2008, 49: 5230-5234. 10.1167/iovs.08-2145.PubMedCentralCrossRefPubMed
2.
Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang H, Carbone M: Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011, 43: 1022-1025. 10.1038/ng.912.PubMedCentralCrossRefPubMed
3.
Martini F, Corallini A, Balatti V, Sabbioni S, Pancaldi C, Tognon M: Simian virus 40 in humans. Infect Agent Cancer. 2007, 2: 13-10.1186/1750-9378-2-13.PubMedCentralCrossRefPubMed
4.
Butel JS: Patterns of polyomavirus SV40 infections and associated cancers in humans: a model. Current opinion in virology. 2012, 2: 508-514. 10.1016/j.coviro.2012.06.004.PubMedCentralCrossRefPubMed
5.
Soriano F, Shelburne CE, Gokcen M: Simian virus 40 in a human cancer. Nature. 1974, 249: 421-424. 10.1038/249421a0.CrossRefPubMed
6.
Corallini A, Mazzoni E, Taronna A, Manfrini M, Carandina G, Guerra G, Guaschino R, Vaniglia F, Magnani C, Casali F, Dolcetti R, Palmonari C, Rezza G, Martini F, Barbanti-Brodano G, Tognon MG: Specific antibodies reacting with simian virus 40 capsid protein mimotopes in serum samples from healthy blood donors. Hum Immunol. 2012, 73: 502-510. 10.1016/j.humimm.2012.02.009.CrossRefPubMed
7.
Barbanti-Brodano G, Sabbioni S, Martini F, Negrini M, Corallini A, Tognon M: BK virus, JC virus and Simian Virus 40 infection in humans, and association with human tumors. Adv Exp Med Biol. 2006, 577: 319-341. 10.1007/0-387-32957-9_23.CrossRefPubMed
8.
Griewank KG, Yu X, Khalili J, Sozen MM, Stempke-Hale K, Bernatchez C, Wardell S, Bastian BC, Woodman SE: Genetic and molecular characterization of uveal melanoma cell lines. Pigment cell & melanoma research. 2012, 25: 182-187. 10.1111/j.1755-148X.2012.00971.x.CrossRef
Metadata
Title
Antibodies reacting with Simian Virus 40 capsid protein mimotopes in serum samples from patients affected by uveal melanoma
Authors
Ilaria Bononi
Paolo Perri
Alice Begnardi
Alessandra Martini
Elisa Mazzoni
Silvia Bosi
Silvia Pietrobon
Adolfo Sebastiani
Mauro Tognon
Fernanda Martini
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2014
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-7-38

Other articles of this Issue 1/2014

Journal of Hematology & Oncology 1/2014 Go to the issue

Case report

Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia

Review

T cell immune abnormalities in immune thrombocytopenia

Research

Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice

Research

Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells

Research

Low expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patients

Research

Developing aptamer probes for acute myelogenous leukemia detection and surface protein biomarker discovery
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits